Account wins from the 02/17/06 News Brief

Share this article:
PDI announced a three-year agreement with Ascend Therapeutics to promote their estrogen replacement therapy product, EstroGel, to the obstetrician/gynecologist market. PDI will initially provide a specialty sales team of 50 field representatives, with the expectation the field force will grow over time. The program is due to run through Jan. 31, 2008, with an automatic extension through Jan. 31, 2009, if certain conditions are met.
Share this article:
You must be a registered member of MMM to post a comment.

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.